查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1525466

全球生物製品安全测试市场评估：依产品和服务、依测试类型、依应用、依最终用户、依地区、机会和预测，2017-2031年

Biologics Safety Testing Market Assessment, By Product and Services, By Test Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Markets & Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

2024-2031年预测期间，全球生物製品安全测试市场规模将以11.80%的年复合成长率扩大，从2023年的40.1亿美元增至2031年的97.9亿美元。该市场是生物技术市场的重要组成部分，受到慢性病患病率上升、技术进步以及投资和资金增加等因素的推动。

生物安全性测试对于确保治疗性生物製剂的有效性和安全性极为重要。儘管现代分子技术早已建立，实验室仍依赖20 世纪 70年代的动物实验方案。最近的指南变化促使生物製药行业转向生物製品品质控制（QC）的新标准，例如基于下一代定序（NGS）的测试，并不再使用动物。单株抗体、疫苗、重组蛋白、病毒载体以及细胞和基因疗法只是属于治疗性生物製品这一广泛类别的众多技术中的一小部分。即使在减少药物开发中使用动物的全球协议之后，动物仍继续广泛用于生物製剂的品质控制测试。这项共识体现在美国和欧盟实施的3R（替代、减少、改进）理念和指令。除了伦理问题之外，动物实验成本高昂，需要数週至数月才能完成。

本报告调查了全球生物製品安全测试市场，并提供了市场概述，以及依产品/服务、测试类型、应用、最终用户、地区划分的趋势和进入市场的公司概况。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章 2017-2031年全球生物製品安全测试市场展望

  • 市场规模分析与预测
  • 市占率分析与预测
  • 2023年市场地图分析
    • 依产品/服务
    • 依考试类型
    • 依用途
    • 依最终用户
    • 依地区

第5章 北美生物製品安全测试市场展望，2017-2031

第6章 欧洲生物製品安全测试市场展望，2017-2031

第7章 亚太地区生物製品安全测试市场展望，2017-2031

第8章 2017-2031年南美洲生物製品安全测试市场展望

第9章 2017-2031年中东与非洲生物製剂安全测试市场展望

第10章 供需分析

第11章 汇出/汇入分析

第12章 价值链分析

第13章 波特五力分析

第14章 PESTLE分析

第15章 价格分析

第16章 市场动态

第17章 市场趋势与发展

第18章 监理架构与创新

第19章 专利现况

第20章 个案研究

第21章 竞争态势

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名进入公司的 SWOT 分析
  • 市场前10位主要参与者的情况
    • Charles River Laboratories International Inc
    • BSL BIOSERVICE Scientific Laboratories Munich GmbH
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • Sartorious AG
    • F.Hoffman-La Roche Ltd
    • Biomerieux SA
    • Eurofins Scientific SE
    • Lonza Group AG
    • Maravai LifeSciences Holdings, Inc.
Product Code: MX11687

Global biologics safety testing market is projected to witness a CAGR of 11.80% during the forecast period 2024-2031, growing from USD 4.01 billion in 2023 to USD 9.79 billion in 2031. This market is an important part of the biotechnology market and is driven by factors such as the increasing prevalence of chronic diseases, technological advancements, and increased investments and funding.

Testing for biologics safety is crucial to guarantee the effectiveness and safety of therapeutic biologics. Modern molecular techniques have been around for a while, yet laboratories still mostly use protocols from the 1970s for animal testing. A recent change to guidelines urges the biopharmaceutical sector to transition to new standards in biologics quality control (QC), such as next-generation sequencing (NGS)-based tests, and to stop using animals. Monoclonal antibodies, vaccines, recombinant proteins, viral vectors, and cell and gene therapies are just a few of the many modalities that fall under the broad category of therapeutic biologics. Animals are still extensively utilized in biologics quality control testing even after there was a global agreement to reduce the use of animals in medication development. This agreement is represented in the 3R (replace, reduce, refine) philosophy and directives put in place in the United States and European Union. Animal-based operations come with a price tag and need weeks or even months to complete, in addition to ethical concerns.

Leading science and technology organization Merck finished the second phase of its new USD 31.41 million Biologics Testing Center expansion in China in November 2023, adding 1,500 square meters to the lab. These are Merck's first biosafety labs in this market, giving customers local access to a wide variety of testing services and cell line characterization from pre-clinical research to commercialization.

Increasing Prevalence of Chronic Diseases

The need for biologics testing is driven mostly by the rising incidence of chronic illnesses. Advanced treatment alternatives, especially biologics like monoclonal antibodies and other targeted medicines, are needed as chronic illnesses like diabetes, cancer, and autoimmune disorders grow increasingly prevalent. Extensive testing is frequently necessary to guarantee the safety and effectiveness of biologics across a range of patient groups. The increasing number of patients related to chronic diseases calls for improved biological testing capacities in order to facilitate the development of customized medicine strategies that address individual patient demands and eventually lead to better treatment results.

According to the British Heart Foundation Report 2024, more than 200 million people globally are living with coronary heart disease. Out of 200 million coronary heart patients, 110 million are men, and 90 million are women. As per the World Health Organization (WHO), in 2022, there were 20 million new cancer patients, and close to 9.7 million patients died due to cancer.

Rising Adoption of Advanced Analytics Solutions in Biologics Safety Testing and Clinical Trials

Healthcare leaders see a wide range of opportunities to improve patient care by bringing data from disparate sources together in a meaningful way. Healthcare professionals believe data-driven insights could help optimize treatment plans and care pathways, identify evidence-based practices, and reduce waiting lists for diagnostic and elective procedures. However, to deliver on these possibilities, healthcare leaders recognize they first need to get the foundations right. The foundation of seamless data integration can be done by improving the accuracy of patient data, improving drug efficacy in biologics testing, enhancing interoperability among different platforms and healthcare settings, and strengthening data security and privacy. Healthcare executives see several chances to enhance patient care via the integration of data from various sources. Healthcare practitioners think data-driven insights might assist in finding evidence-based treatments, streamline treatment plans and care pathways, and shorten waiting lists for elective and diagnostic procedures. Healthcare executives understand that, in order to fully realize these opportunities, they must first lay the necessary groundwork. Improving patient data accuracy, boosting platform and healthcare setting interoperability, and fortifying data security and privacy are the cornerstones of a smooth data integration process.

In 2024, Yotta Data Services Pvt Ltd. announced a partnership with Partex NV to improve healthcare services in drug discovery and patient care. The partnership will leverage Yotta's Shakti-Cloud platform, backed by Nvidia H100 GPU processing infrastructure, to enable Partex's AI-driven healthcare solutions. The collaboration intends to create AI-based solutions that will improve healthcare services' efficacy and efficiency, especially in the areas of patient care and drug development.

Residual Host Contamination Detection Tests Dominate the Market

Biologics safety testing can be divided into the following categories - residual host contamination detection tests, adventitious agent detection tests, bioburden tests, cell line authentication & characterization tests, sterility tests, endotoxin tests, and many others. Assays for detecting residual host contamination are crucial to the biopharmaceutical industry and testing for residual host cell DNA (HCDNA) is one area of particular importance. These tests aim to locate and quantify any host cell DNA that is still needed to produce biologics, such as therapeutic proteins and vaccines. These tests usually employ sensitive techniques, such as Polymerase Chain Reaction (PCR), to identify and measure any leftover DNA remains. Modern technologies enable the identification of even minute amounts, which is crucial for ensuring the safety of products. Tests for residual host contamination provide strong regulatory compliance, enhanced safety, and quality assurance, among other clinical benefits.

Pharmaceutical and Biotechnology Companies Dominate the Market

To guarantee the effectiveness and safety of biologics such as therapeutic proteins and vaccines, pharmaceutical and biotechnology businesses are essential to the safety testing process of biologics. Throughout the development process, these businesses oversee carrying out thorough evaluations that involve testing for toxins, leftover host cell proteins, and viral safety. Advanced testing procedures are necessary to address specific safety issues related to various biologics products because of the complexity and variety of biologics. For instance, Skan AG, a leader in cleanroom technology, decontamination procedures, and isolators for the aseptic manufacturing of biopharmaceuticals launched Claire Neo in June 2024. Claire Neo is a new line of safety cabinets designed to suit future laboratory standards in the pharmaceutical, medical, and biological sectors. Users may be as flexible as possible with the new safety cabinets. The manufacture in metric increments of 30 cm is the main emphasis of this new flexibility.

Future Market Scenario (2024-2031F)

Integration of Bioinformatics and Data Analytics: Bioinformatics will enable the integration and analysis of large datasets generated during biologics safety testing. This will help identify trends, understand complex interactions, and ensure compliance with regulatory standards, ultimately enhancing the overall safety profile of biologic therapies.

Introduction of Rapid Microbiological Methods: The development and implementation of rapid microbiological testing techniques will facilitate quicker detection of microbial contamination in biologics. These methods can provide results in real-time, which is crucial for maintaining the safety and quality of biologic products during manufacturing.

NGS Will Become an Important Part of Biologics Testing: The adoption of NGS in safety testing will allow for comprehensive analysis of genetic material in biologics, enabling the detection of contaminants and residual host cell DNA with greater precision. This technology can significantly improve the reliability of safety assessments.

Key Player Landscape and Outlook

Key players in this sector, including Charles River Laboratories International, Inc., BSL BIOSERVICE Scientific Laboratories Munich GmbH, Merck KGaA, Thermo Fisher Scientific Inc., Sartorious AG, F.Hoffman-La Roche Ltd, Biomerieux SA, Eurofins Scientific SE, Lonza Group AG, Maravai LifeSciences Holdings, Inc. are actively enhancing their service offerings and expanding their technological capabilities to meet stringent regulatory standards and ensure the safety of biologics. Companies are also engaging in strategic acquisitions and partnerships to bolster their market positions and improve testing methodologies, thereby addressing the increasing demand for comprehensive safety evaluations in the biopharmaceutical industry.

SAMDI Tech, Inc., a provider of high-throughput screening (HTS) technologies, was acquired by Charles River Laboratories, Inc. in January 2023. By utilizing SAMDI Tech's technology to speed up the identification of viable drug candidates, this acquisition seeks to improve drug discovery procedures.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Biologics Safety Testing Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product and Services
      • 4.2.1.1. Consumables
      • 4.2.1.2. Instruments
      • 4.2.1.3. Services
        • 4.2.1.3.1. Mycoplasma Testing Services
        • 4.2.1.3.2. Sterility Testing Services
        • 4.2.1.3.3. Endotoxin Testing Services
        • 4.2.1.3.4. Virus Safety Testing Services
        • 4.2.1.3.5. Bioburden Testing Services
        • 4.2.1.3.6. Others
    • 4.2.2. By Test Type
      • 4.2.2.1. Residual Host Contamination Detection Tests
      • 4.2.2.2. Adventitious Agent Detection Tests
      • 4.2.2.3. Bioburden Tests
      • 4.2.2.4. Cell Line Authentication and Characterization Tests
      • 4.2.2.5. Sterility Tests
      • 4.2.2.6. Endotoxin Tests
      • 4.2.2.7. Others
    • 4.2.3. By Application
      • 4.2.3.1. Vaccines and Therapeutics
      • 4.2.3.2. Blood and Blood-based Products
      • 4.2.3.3. Gene Therapy
      • 4.2.3.4. Tissue and Tissue-based Products
      • 4.2.3.5. Stem Cell
    • 4.2.4. By End-user
      • 4.2.4.1. Pharmaceutical and Biotechnology Companies
      • 4.2.4.2. CRO and CDMOs
      • 4.2.4.3. Academic and Research Institutes
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Product and Services
    • 4.3.2. By Test Type
    • 4.3.3. By Application
    • 4.3.4. By End-user
    • 4.3.5. By Region

5. North America Biologics Safety Testing Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product and Services
      • 5.2.1.1. Consumables
      • 5.2.1.2. Instruments
      • 5.2.1.3. Services
        • 5.2.1.3.1. Mycoplasma Testing Services
        • 5.2.1.3.2. Sterility Testing Services
        • 5.2.1.3.3. Endotoxin Testing Services
        • 5.2.1.3.4. Virus Safety Testing Services
        • 5.2.1.3.5. Bioburden Testing Services
        • 5.2.1.3.6. Others
    • 5.2.2. By Test Type
      • 5.2.2.1. Residual Host Contamination Detection Tests
      • 5.2.2.2. Adventitious Agent Detection Tests
      • 5.2.2.3. Bioburden Tests
      • 5.2.2.4. Cell Line Authentication and Characterization Tests
      • 5.2.2.5. Sterility Tests
      • 5.2.2.6. Endotoxin Tests
      • 5.2.2.7. Others
    • 5.2.3. By Application
      • 5.2.3.1. Vaccines and Therapeutics
      • 5.2.3.2. Blood and Blood-based Products
      • 5.2.3.3. Gene Therapy
      • 5.2.3.4. Tissue and Tissue-based Products
      • 5.2.3.5. Stem Cell
    • 5.2.4. By End-user
      • 5.2.4.1. Pharmaceutical and Biotechnology Companies
      • 5.2.4.2. CRO and CDMOs
      • 5.2.4.3. Academic and Research Institutes
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Biologics Safety Testing Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
        • 5.3.1.1.2. By Volume
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Product and Services
          • 5.3.1.2.1.1. Consumables
          • 5.3.1.2.1.2. Instruments
          • 5.3.1.2.1.3. Services
          • 5.3.1.2.1.3.1. Mycoplasma Testing Services
          • 5.3.1.2.1.3.2. Sterility Testing Services
          • 5.3.1.2.1.3.3. Endotoxin Testing Services
          • 5.3.1.2.1.3.4. Virus Safety Testing Services
          • 5.3.1.2.1.3.5. Bioburden Testing Services
          • 5.3.1.2.1.3.6. Others
        • 5.3.1.2.2. By Test Type
          • 5.3.1.2.2.1. Residual Host Contamination Detection Tests
          • 5.3.1.2.2.2. Adventitious Agent Detection Tests
          • 5.3.1.2.2.3. Bioburden Tests
          • 5.3.1.2.2.4. Cell Line Authentication and Characterization Tests
          • 5.3.1.2.2.5. Sterility Tests
          • 5.3.1.2.2.6. Endotoxin Tests
          • 5.3.1.2.2.7. Others
        • 5.3.1.2.3. By Application
          • 5.3.1.2.3.1. Vaccines and Therapeutics
          • 5.3.1.2.3.2. Blood and Blood-based Products
          • 5.3.1.2.3.3. Gene Therapy
          • 5.3.1.2.3.4. Tissue and Tissue-based Products
          • 5.3.1.2.3.5. Stem Cell
        • 5.3.1.2.4. By End-user
          • 5.3.1.2.4.1. Pharmaceutical and Biotechnology Companies
          • 5.3.1.2.4.2. CRO and CDMOs
          • 5.3.1.2.4.3. Academic and Research Institutes
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Biologics Safety Testing Market Outlook, 2017-2031F

    • 6.1.1. Germany
    • 6.1.2. France
    • 6.1.3. Italy
    • 6.1.4. United Kingdom
    • 6.1.5. Russia
    • 6.1.6. Netherlands
    • 6.1.7. Spain
    • 6.1.8. Turkey
    • 6.1.9. Poland

7. Asia-Pacific Biologics Safety Testing Market Outlook, 2017-2031F

    • 7.1.1. India
    • 7.1.2. China
    • 7.1.3. Japan
    • 7.1.4. Australia
    • 7.1.5. Vietnam
    • 7.1.6. South Korea
    • 7.1.7. Indonesia
    • 7.1.8. Philippines

8. South America Biologics Safety Testing Market Outlook, 2017-2031F

    • 8.1.1. Brazil
    • 8.1.2. Argentina

9. Middle East and Africa Biologics Safety Testing Market Outlook, 2017-2031F

    • 9.1.1. Saudi Arabia
    • 9.1.2. UAE
    • 9.1.3. South Africa

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape20. Case Studies

21. Competitive Landscape

  • 1.1. Competition Matrix of Top 5 Market Leaders
  • 1.2. SWOT Analysis for Top 5 Players
  • 1.3. Key Players Landscape for Top 10 Market Players
    • 1.3.1. Charles River Laboratories International Inc
      • 1.3.1.1. Company Details
      • 1.3.1.2. Key Management Personnel
      • 1.3.1.3. Products and Services
      • 1.3.1.4. Financials (As Reported)
      • 1.3.1.5. Key Market Focus and Geographical Presence
      • 1.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 1.3.2. BSL BIOSERVICE Scientific Laboratories Munich GmbH
    • 1.3.3. Merck KGaA
    • 1.3.4. Thermo Fisher Scientific Inc.
    • 1.3.5. Sartorious AG
    • 1.3.6. F.Hoffman-La Roche Ltd
    • 1.3.7. Biomerieux SA
    • 1.3.8. Eurofins Scientific SE
    • 1.3.9. Lonza Group AG
    • 1.3.10. Maravai LifeSciences Holdings, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.22. Strategic Recommendations23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 4. Global Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 5. Global Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 6. Global Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Biologics Safety Testing Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10. North America Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 11. North America Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 12. North America Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Biologics Safety Testing Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17. United States Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 18. United States Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 19. United States Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 20. United States Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23. Canada Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 24. Canada Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 25. Canada Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 26. Canada Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29. Mexico Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 30. Mexico Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 31. Mexico Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 32. Mexico Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35. Europe Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 36. Europe Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 37. Europe Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 38. Europe Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Biologics Safety Testing Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42. Germany Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 43. Germany Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 44. Germany Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 45. Germany Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. France Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 49. France Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 50. France Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 51. France Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54. Italy Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 55. Italy Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 56. Italy Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 57. Italy Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60. United Kingdom Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 61. United Kingdom Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 62. United Kingdom Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 63. United Kingdom Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66. Russia Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 67. Russia Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 68. Russia Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 69. Russia Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72. Netherlands Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 73. Netherlands Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 74. Netherlands Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 75. Netherlands Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78. Spain Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 79. Spain Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 80. Spain Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 81. Spain Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84. Turkey Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 85. Turkey Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 86. Turkey Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 87. Turkey Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Poland Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 91. Poland Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 92. Poland Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 93. Poland Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96. South America Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 97. South America Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 98. South America Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 99. South America Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Biologics Safety Testing Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103. Brazil Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 104. Brazil Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 105. Brazil Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 106. Brazil Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109. Argentina Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 110. Argentina Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 111. Argentina Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 112. Argentina Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115. Asia-Pacific Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 116. Asia-Pacific Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 117. Asia-Pacific Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 118. Asia-Pacific Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Biologics Safety Testing Market Share (%), By Country, 2017-2031F
  • Figure 120. India Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122. India Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 123. India Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 124. India Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 125. India Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128. China Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 129. China Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 130. China Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 131. China Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134. Japan Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 135. Japan Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 136. Japan Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 137. Japan Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140. Australia Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 141. Australia Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 142. Australia Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 143. Australia Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146. Vietnam Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 147. Vietnam Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 148. Vietnam Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 149. Vietnam Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152. South Korea Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 153. South Korea Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 154. South Korea Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 155. South Korea Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158. Indonesia Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 159. Indonesia Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 160. Indonesia Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 161. Indonesia Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164. Philippines Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 165. Philippines Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 166. Philippines Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 167. Philippines Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170. Middle East & Africa Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 171. Middle East & Africa Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 172. Middle East & Africa Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 173. Middle East & Africa Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Biologics Safety Testing Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177. Saudi Arabia Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 178. Saudi Arabia Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 179. Saudi Arabia Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 180. Saudi Arabia Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. UAE Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 184. UAE Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 185. UAE Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 186. UAE Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Biologics Safety Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Biologics Safety Testing Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189. South Africa Biologics Safety Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 190. South Africa Biologics Safety Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 191. South Africa Biologics Safety Testing Market Share (%), By Application, 2017-2031F
  • Figure 192. South Africa Biologics Safety Testing Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Product and Services Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023